Advanced search
Start date

Metabolomic strategies based on LC-HRMS for investigation of potential biomarkers for clinical diagnosis - Phase I


Metabolomics is an emerging technology that is gaining attention in both basic science and human applications, providing an instant physiological snapshot. It has been highlighted as one of the widest ranging and reliable tools for the investigation of physiological status, the discovery of new biomarkers and the analysis of metabolic pathways. Metabolomics uses innovative mass spectrometry (MS) allied to liquid chromatography to improve selectivity. The recent advances in bioinformatics, databases, and statistics have provided a unique perception of metabolites interaction and the dynamics of metabolic pathways at a system level. In this context, several studies have applied metabolomics in physiology and disease-related works. The application of metabolomics includes, physiological and metabolic evaluation/monitoring, individual response to different exercise, nutritional interventions, pathological processes, responses to pharmacological interventions, biomarker discovery and monitoring for distinct aspects, such as: physiological capacity, fatigue/recovery and aging, among other applications. However, despite major improvements in the analytical strategies used, several stages of analytical and statistical development are still complex, but crucial for the generation of robust and high-quality data. Metabolomics is a discipline that provides an accurate and dynamic image of the phenotype of biological systems through the study of endogenous and exogenous metabolites in cells, tissues, and biofluids. In particular, the metabolic fingerprint, the global analysis of tissues and biofluids, seeks to fingerprint and semi-quantify the metabolites and their changes, revealing information about the general metabolic status of individuals. The objective of this research project is to identify metabolites related to autoimmune biliary diseases and rare diseases, such as Bartter's Syndrome. The metabolites identified could be used as biomarkers for the diagnosis of these diseases in less time and with simpler tests, as well as providing a more personalized and assertive drug therapy. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
LONG, SOLIDA; FURLANI, IZADORA L.; DE OLIVEIRA, JULIANA M.; RESENDE, DIANA I. S. P.; SILVA, ARTUR M. S.; GALES, LUIS; PEREIRA, JOSE A.; KIJJOA, ANAKE; CASS, QUEZIA B.; OLIVEIRA, REGINA V.; et al. Determination of the Absolute Configuration of Bioactive Indole-Containing Pyrazino[2,1-b]quinazoline-3,6-diones and Study of Their In Vitro Metabolic Profile. Molecules, v. 26, n. 16, . (18/03035-3, 20/05965-8, 19/15040-4)
OLIVEIRA, REGINA V.; SIMIONATO, ANA VALERIA C.; CASS, QUEZIA B.. Enantioselectivity Effects in Clinical Metabolomics and Lipidomics. Molecules, v. 26, n. 17, . (20/05965-8)

Please report errors in scientific publications list by writing to: